Figure 1: Genome-wide occupancy of BRM and REF6. Figure 2 ... Nuclear proteins were released by incubating the nuclei preparation in 120 μl of lysis buffer (50 mM Tris-HCl, 10 mM EDTA, 1% ...

Poster 3230 / 14: Discovery of selective BRM (SMARCA2) ATPase inhibitors for the treatment of BRG1 (SMARCA4) mutant cancersPreclinical data presented at AACR support FHD-909 as an oral ...

“We are excited to present new preclinical data supporting the potent activity of FHD-909, a potentially first-in-class oral BRM selective inhibitor with robust anti-tumor activity, and we look ...

today announced preclinical data supporting the clinical development and mechanistic understanding of BAF inhibition through the BRG1 (SMARCA4) and BRM (SMARCA2) dual inhibitor, FHD-286 ...

Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024 Oral ...